Old National Bancorp
Change company Symbol lookup
Select an option...
ONB Old National Bancorp
TIG Trean Insurance Group Inc
DICE Dice Therapeutics Inc
NUSI Nationwide Nasdaq-100® Risk-Managed Income ETF
TISI Team Inc
UIHC United Insurance Holdings Corp
BFI Burgerfi International Inc
COW iPath? Series B Bloomberg Livestock Subindex Total Return ETN
PYXS Pyxis Oncology Inc

Financials : Banks | Small Cap Value
Company profile

Old National Bancorp is a financial holding company. The Company, through its wholly owned banking subsidiary, Old National Bank, provides a range of services, including commercial and consumer loan and depository services, private banking, brokerage, trust, investment advisory, and other banking services. Its banking centers focuses on providing a group of community banking services. It provides treasury management, merchant, and capital markets services as well as community development lending and equity investment solutions for businesses. Its loans consist primarily of loans made to consumers and commercial clients in various industries, including real estate rental and leasing, manufacturing, wholesale trade, construction, and agriculture, among others. In addition to providing lending and deposit services, it offers wealth management, investment, and foreign currency services. Its banking centers are in Illinois, Indiana, Iowa, Kentucky, Michigan, Minnesota, and Wisconsin.


Last Trade
0.73 (5.05%)
B/A Size

Market Hours

Closing Price
Day's Change
-0.72 (-4.74%)
Bid close
Ask close
B/A Size
Day's High
Day's Low

10-day average volume:

Bristol Myers Squibb sees revenue fall in Q4

7:21 am ET February 2, 2023 (MarketWatch)

Shares of Bristol Myers Squibb Co. (BMY) gained 0.9% in premarket trading on Thursday after the company announced better-than-expected earnings for the fourth quarter of 2022. Bristol Myers Squibb had a profit of $2.0 billion, or 95 cents per share, in the fourth quarter, down from $2.3 billion, or $1.07 per share, in the same quarter in 2021. Adjusted earnings per share came in at $1.82, against the FactSet consensus of $1.73. Bristol Myers Squibb had revenue of $11.4 billion for the quarter, down from $11.9 billion in the same quarter in 2021. The FactSet consensus was $11.2 billion. The company blamed the revenue loss of exclusivity on products like Revlimid, its multiple myeloma treatment, which had $2.2 billion in sales for the fourth quarter of 2022, compared with $3.3 billion in the final three months of 2021. The consensus was $1.9 billion. Bristol said it expects to have adjusted EPS of $7.95 to $8.25 in 2023. The company's stock is up 9.9% over the past year, while the broader S&P 500 is down 7.9%.

-Jaimy Lee


(END) Dow Jones Newswires

February 02, 2023 07:21 ET (12:21 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.